Blueprint Medicines (NASDAQ:BPMC) Lifted to “Strong-Buy” at Baird R W
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by stock analysts at Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. BPMC has been the topic of a number of other reports. Barclays upped their price target on Blueprint Medicines from $75.00 to […]
More Stories
Editor-in-Chief of America’s Oldest Magazine Resigns After Denigrating Trump Voters
By Zachary Stieber The editor-in-chief of Scientific American, which was founded in 1845, has stepped down after calling people who...
Empirical Finance LLC Acquires 380 Shares of Amgen Inc. (NASDAQ:AMGN)
Empirical Finance LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.1% during the third...
First Long Island Investors LLC Lowers Stake in Stryker Co. (NYSE:SYK)
First Long Island Investors LLC lessened its holdings in Stryker Co. (NYSE:SYK – Free Report) by 3.8% during the third...
Global Industrial (NYSE:GIC) Short Interest Up 27.2% in October
Global Industrial (NYSE:GIC – Get Free Report) was the target of a large increase in short interest during the month...
MicroStrategy (NASDAQ:MSTR) Trading 1.1% Higher – Here’s What Happened
MicroStrategy Incorporated (NASDAQ:MSTR – Get Free Report)’s share price traded up 1.1% on Friday . The company traded as high...
First Trust Municipal High Income ETF (NASDAQ:FMHI) Short Interest Update
First Trust Municipal High Income ETF (NASDAQ:FMHI – Get Free Report) was the recipient of a significant increase in short...